HC Wainwright Analysts Reduce Earnings Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Analysts at HC Wainwright dropped their Q3 2024 EPS estimates for Day One Biopharmaceuticals in a research report issued on Wednesday, July 31st. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.73) per share for the quarter, down from their previous forecast of ($0.69). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.29) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q4 2024 earnings at ($0.73) EPS, FY2024 earnings at ($2.23) EPS, FY2025 earnings at ($2.03) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at $0.62 EPS and FY2028 earnings at $1.57 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.70. The business had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $0.90 million.

DAWN has been the subject of several other reports. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price target for the company from $11.00 to $24.00 in a report on Thursday, August 1st. JPMorgan Chase & Co. decreased their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, July 30th. Finally, Piper Sandler restated an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Stock Down 1.1 %

Shares of NASDAQ DAWN opened at $13.11 on Monday. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -5.22 and a beta of -1.51. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $18.07. The firm has a 50-day moving average price of $13.99 and a 200 day moving average price of $14.84.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $16.37, for a total value of $163,700.00. Following the sale, the insider now directly owns 1,164,662 shares of the company’s stock, valued at $19,065,516.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Samuel C. Blackman sold 20,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total transaction of $320,200.00. Following the sale, the insider now owns 1,121,081 shares of the company’s stock, valued at $17,948,506.81. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $16.37, for a total value of $163,700.00. Following the transaction, the insider now owns 1,164,662 shares of the company’s stock, valued at $19,065,516.94. The disclosure for this sale can be found here. Insiders sold 56,068 shares of company stock worth $874,173 in the last 90 days. 8.40% of the stock is currently owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. First Turn Management LLC acquired a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at $24,834,000. Estuary Capital Management LP raised its position in shares of Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after buying an additional 728,240 shares in the last quarter. TimesSquare Capital Management LLC lifted its stake in shares of Day One Biopharmaceuticals by 45.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 1,666,065 shares of the company’s stock worth $24,325,000 after acquiring an additional 523,455 shares during the period. Braidwell LP boosted its holdings in shares of Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after acquiring an additional 500,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the period. Institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.